Premium
Inhibitors of heat shock proteins in cancer treatment
Author(s) -
Chiosis Gabriela
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.230.1
Subject(s) - heat shock protein , cancer cell , phenotype , cancer , neurodegeneration , translation (biology) , biology , cancer research , hsp90 , hsp70 , programmed cell death , microbiology and biotechnology , apoptosis , medicine , disease , messenger rna , genetics , gene , pathology
In many diseases, among which cancer and neurodegeneration, the development of a pathogenic phenotype is associated with dysregulation of multiple pathways and molecules. To adapt, cells co‐opt heat shock proteins (HSPs) to help maintain a functional cellular state under the transforming pressure. As such, cancer cells often express high levels of several HSPs, which augment the aggressiveness of these tumors and also allow the cells to survive lethal conditions, including killing by therapies. In addition to conferring resistance to treatment, elevated HSP expression also facilitates cancer by inhibiting programmed cell death and by promoting autonomous growth. Among the major HSPs are Hsp90 and Hsp70, proteins that act in an interconnected but also distinct fashion to regulate the malignant phenotype. Consequently, approaches that target these HSPs are especially powerful in treating cancer and in overcoming resistance to current treatments. This talk will present some of our efforts in the design, development and clinical translation of these inhibitors as potential novel therapies in cancer.